The next step would be formally opening an in-depth probe of the iRobot deal, which the people said is expected given the detailed questions from agency officials. Both were granted anonymity to discuss a confidential investigation.

The FTC’s iRobot review is wide-ranging, one of the people said, including both head-to-head competition and whether the deal will illegally boost Amazon’s market share in both the connected device market and the retail market generally. Amazon also sells a high-end robot vacuum that has failed to gain traction with consumers. The FTC is also investigating how the purchase would add to Amazon’s increasing smart device lineup, which also includes Ring security cameras and the Alexa digital assistant.

Among the concerns the FTC is investigating is whether the data generated about a consumer’s home by iRobot’s Roomba vacuum will give it an unfair advantage over a wide variety of other retailers. That concern was voiced by multiple critics of the deal when it was first announced early this month. For example, Amazon could have an advantage with a consumer looking to buy a couch, by using detailed home maps generated by iRobot to suggested particular items.

And the iRobot review comes as the FTC is also pushing further ahead with scrutiny of another deal. On Friday, 1Life Healthcare — which operates the primary care provider One Medical — disclosed that the FTC opened up an in-depth review of its takeover by Amazon. The two deals were announced less than three weeks apart this summer.

One Medical is a membership-based primary care provider, with locations around the U.S. Amazon is shutting down a similar service, a fact that could draw censure from the FTC, which could interpret the move as Amazon choosing to buy a competitor rather than compete with it.

In the One Medical deal the FTC is asking questions about the data Amazon would have access to, querying insurance companies and others about how One Medical’s patient data would potentially give it an advantage over competitors and customers, according to a person with knowledge of that review. That individual was granted anonymity because that information is part of the confidential investigation.

The FTC, One Medical and iRobot did not immediately respond for comment.

Amazon declined to comment on either view. The company did reiterate its past statements about both deals, saying it will employ all necessary safeguards for consumer data, including health care information.